Faith Zaslavsky
About Faith Zaslavsky
Faith Zaslavsky, age 50, is Chief Executive Officer of IMAC Holdings (ticker: BACK), appointed on May 23, 2024. She previously served as CEO (since June 2023) and President/COO (since December 2022) of Theralink Technologies, and earlier was President of Oncology for Myriad Genetic Laboratories; she also serves on the board of the American Society of Breast Surgeons Foundation . Filings for FY2024 show salary-only compensation (no bonus/equity awards) and do not disclose TSR, revenue/EBITDA targets or other performance metrics tied to her pay for 2024 .
Past Roles
| Organization | Role | Years | Strategic impact |
|---|---|---|---|
| Theralink Technologies, Inc. | Chief Executive Officer | 2023–2024 | Led oncology proteomics company; transitioned to IMAC CEO in May 2024 |
| Theralink Technologies, Inc. | President & COO | 2022–2023 | Senior operating leadership prior to CEO role |
| Myriad Genetic Laboratories | President, Oncology | Not disclosed | Oversaw commercial functions (Medical Services, Medical Affairs, Accounts, Sales/Marketing) |
External Roles
| Organization | Role | Years |
|---|---|---|
| American Society of Breast Surgeons Foundation | Board of Directors | Not disclosed |
Fixed Compensation
| Metric | 2023 | 2024 |
|---|---|---|
| Base Salary ($) | — | 262,713 |
| Cash Bonus ($) | — | 0 (no bonus reported) |
Performance Compensation
| Component | FY 2024 Amount/Status | Notes |
|---|---|---|
| Annual cash bonus | $0 | No bonus paid or metric disclosure in filings |
| Stock awards (RSUs/PSUs) | $0 | No grants reported for 2024 |
| Option awards | $0 | No grants reported for 2024 |
| Performance metrics/weightings | Not disclosed | No payout framework disclosed for 2024 |
Equity Ownership & Alignment
| Metric | As of Jul 17, 2024 (record date) | As of Jan 27, 2025 (record date) |
|---|---|---|
| Shares beneficially owned | — (none reported) | — (none reported) |
| Ownership % of outstanding | — (1,721,819 shares outstanding) | — (2,071,812 shares outstanding) |
| Vested vs. unvested equity | None disclosed | None disclosed |
| Options (exercisable/unexercisable) | None disclosed | None disclosed |
| Shares pledged as collateral | Not disclosed | Not disclosed |
| Insider trading/hedging policy | Short sales prohibited; hedging discouraged; pre-clearance required | Short sales prohibited; hedging discouraged; pre-clearance required |
Filings show no Form 14A beneficial ownership for Zaslavsky at both record dates and no 2024 equity awards, implying limited immediate equity alignment as disclosed at those times .
Employment Terms
| Term | Detail |
|---|---|
| Employment start (CEO) | May 23, 2024 |
| Contract term/expiration | Not disclosed (no Zaslavsky employment agreement described; Employment Agreements section references prior CEO only) |
| Severance (salary/bonus multiples) | Not disclosed for Zaslavsky |
| Change-of-control treatment | Not disclosed for Zaslavsky |
| Non-compete / non-solicit | Not disclosed for Zaslavsky |
| Clawback policy | Company adopted clawback in 2023 pursuant to SEC/Nasdaq rules |
| Equity plan capacity | 2018 Plan increased to 566,667 shares (if approved), enabling future grants |
| Insider policy | Hedging discouraged; short sales prohibited; pre-clearance required |
Investment Implications
- Pay-for-performance alignment appears limited for FY2024: filings report salary-only compensation for the CEO with no cash bonus or equity grants and no disclosed performance metrics for payout, reducing near-term variable incentive linkage .
- Skin-in-the-game: beneficial ownership tables list no shares for Zaslavsky at both the 2024 and early-2025 record dates, indicating minimal disclosed ownership alignment at those points in time .
- Governance protections: a clawback policy is in place, and the insider trading policy prohibits short sales and discourages hedging, which modestly supports shareholder alignment and risk controls .
- Execution/controls context: the company disclosed internal control weaknesses and reliance on consulting support for GAAP/accounting (June 2025 10-K/A), an operational risk backdrop during her tenure that may require continued remediation focus .
- Future incentive capacity: shareholders were asked to expand equity plan capacity in 2024, which, if utilized, could increase long-term equity alignment once awards are granted to senior executives .